Trial Profile
A single and multiple ascending dose Phase 1 clinical trial of ADX-629
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Apr 2020
Price :
$35
*
At a glance
- Drugs ADX-629 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- 14 Apr 2020 Top-line results presented in an Aldeyra Therapeutics media release.
- 12 Mar 2020 According to an Aldeyra Therapeutics media release, clinical trial has been completed and Top-line results are expected in the second quarter of this year
- 12 Mar 2020 Status changed from recruiting to completed, according to an Aldeyra Therapeutics media release